One-Of-A-Kind Experience Comes to CHOC – Jan. 21st – 31st

“Something tells me that there is a really big change in the air. Do you feel it too?” – Dottie

In partnership with the entertainment experts at the Disneyland Resort, CHOC Children’s is pleased to present the CHOC Showcase to all Associates, Medical Staff and Volunteers.  This one-hour, live-action event highlights the innovative features of the new CHOC Children’s – our culture and our South Tower.  Running at various times January 21 through January 31, 2013, the Showcase is located in Suite 150 of the CHOC Commerce Tower.

Given your valuable role at CHOC, we hope you will attend one of the performances. Featuring entertaining videos and professional actors, the Showcase is unlike anything ever hosted at CHOC.  As we enter the most dynamic era in our history, you won’t want to miss out on this exciting opportunity to learn why CHOC Children’s future is brighter than ever!

Please note: Campus physicians please park in your usual parking location. Community physicians may park in the CHOC Commerce Tower parking lot located at 505 S. Main St.  Validation will be provided at the end of the Showcase.

For more information, show schedule, and to reserve your spot at this exclusive event, please visit

Should you have any questions, please email

Why Do Research in Children? (Clinical Trial Guidelines)

One or more medications are prescribed at nearly half of all children’s doctor visits in this country yet upwards of 30% of these medicines have not undergone the rigors of clinical testing in children.

Even though pediatricians agree that children and adolescent are not just “mini adults”, the off-label use of adult-approved drugs, adjusted for weight, is common in the treatment in these populations. While this may sound like “guesswork,” it’s really more of a ‘hand-me-down’ approach and often the only real choice available to physicians when treating childhood conditions that also affect adults.

Without controlled clinical research in children, a child becomes an experiment of one each time a drug or device is prescribed off-label – only unlike a controlled scientific “experiment”, no statistically tested data are collected that might inform the larger medical community.

To address the gap in knowledge about the specific action of FDA approved drugs for adults prescribed off-label for the treatment of children, pediatricians, the FDA, the National Institutes of Health, and other federal entities are encouraging FDA approved drug and device studies in children.

With easy access to on-line information, parents are likely to hear about clinical trials and want to know more. The Q&As below are intended to aid clinicians in discussing clinical trial options with patients and parents:

Why is clinical research in children and adolescents necessary?

Clinical research in children and adolescents allows physicians to better treat these populations by:

• Finding the best dose of medicines to prevent harmful effects or under-treatment.

• Making chewables, liquids or tablets that are easier for children to take, yet still safe.

• Finding treatments for problems that occur only in children, like prematurity.

• Finding treatments for diseases or conditions that occur in children, adolescents and adults but which can act differently in each sub-population, like arthritis or heart disease.

• Finding treatments for new or existing diseases to improve the health of children in the future, like vaccine studies that were done years ago help children stay healthier today.

• Understanding how medicines affect children and adolescent brains and bodies as they grow and develop.

Can you point to some of the successes with children from clinical trials research in the past?

Yes, here are several important examples:

• Clinical trials showed that surfactant—a substance that keeps air sacs in the lungs inflated—helps premature infants breathe. As a result, the lives of thousands of babies who would otherwise die of respiratory failure are saved each year.

• As a result of repeated clinical trials in children with cancer, most children who develop leukemia survive. Only 50 years ago, acute leukemia was almost universally fatal in young children.

• Prior to the development of the polio vaccine, 15,000 American children developed paralytic polio each year. In the last five years, there have been no cases of paralytic polio in the United States. This advance was only possible through clinical trials in children.

Will my child benefit from participating in a clinical trial?

In general terms, there are some data to suggest that people who participate in clinical research have better outcomes compared to similar patients with the same disease.The reason why research participants tend to fare better is unclear. Improved outcomes may relate to the close observation often demanded by clinical trials, or closer follow-up after care that is often dictated by the research. Children may benefit from participating in clinical research of new medicines because these medicines are usually tested and proven to be safe and effective in adults before they are studied in clinical trials in children.

These short-term benefits are small in comparison to the benefits that will certainly be recognized by future children.

Who is watching out for my child in a study?

The answer is – lots of people. Many qualified professionals review a study in detail before a single person is enrolled. These people include:

•  the scientists who focus on identifying the right treatment,

•  the statisticians who help to design the right study with the right number of participants to get good results,

•  the medical investigators (nurses, doctors, pharmacists, psychologists, and technicians) who will make sure that the study is done in the right way with the right participants, and

•  Institutional Review Boards (IRB) are independent committees that review research plans and consent forms to make sure that people in a study are informed and protected. They review studies both before they start and throughout the study.

What Is “Informed Consent”?

Before you decide whether or not your child should participate in a clinical trial, you should learn the key facts about it. To help you decide, the investigators involved in the study explain its details. If you agree to participate, you give your informed consent. Informed consent is not a contract. You may withdraw from the trial at any time and for any reason.

If I find a clinical trial on-line, how do I discuss it with my doctor?

• Write down a list of questions at home and take it with you when you meet with your doctor. Make sure you get all of your questions answered.

• Take notes during the discussion. Read the notes back to the doctor to make sure you have heard everything correctly.

• Ask what information is already known about the medical product that your child may be given. Studies may be in progress elsewhere and some data may be available.

• Ask for contact information if you would like to talk to other parents whose child is participating in the study. The study team can provide this information if they get permission from other parents to have you contact them.

• After being presented with information and an informed consent document, you do not have to sign it right away. Go home and think about it, talk it over with your family, your child’s pediatrician, and other trusted people.

How do I find out more about clinical trials?

More information about having your child participate in a clinical trial is available at government Web sites, such as:





CHOC Children’s currently has 378 open studies across multiple diseases.

For more information, please contact the CHOC Children’s Research Institute at (714) 590-4341 or visit our Web site at


MI2: Technological Insights for Your Inner Medical “Geek”

Do emerging technologies such as regenerative medicine, nanotechnology and artificial intelligence ignite your intellectual curiosity? If so, you’ll definitely want to get involved with Medical Intelligence & Innovations Group (MI2), which meets monthly at CHOC Children’s.

This informal venue is open to the CHOC Children’s campus and affiliated medical community members interested in exchanging news, information or ideas concerning emerging medical technology and future trends in medicine. Specific areas of interest include genomic medicine, regenerative medicine, robotic surgery, nanotechnology and artificial intelligence.

Recent presentations and discussions have included:

  • Artifical intelligence and human-computer interface
  • Tissue engineering and “personalized” medicine
  • Wireless tools, tests and apps bringing diagnostic information to the bedside
  • Genome sequencing used to halt the recent MRSA outbreak
  • Biocompatible hydrogels via dynamic optical projection stereolithography (DOPsL)        biofabrications for regenerative medicine
  • Transient/dissolvable electronics • Nanotechnology and glucose-powered fuel cells
  • Nobel-winning work in stem cells, cell signaling and G protein-coupled receptors (GPCRs)
  • Crowdfunding and other National Institute of Health (NIH)-funding alternatives
  • Cyperspace security

Developed by CHOC physicians Anthony Chang, M.D., medical director, CHOC Children’s Heart Institute and Nick Anas, M.D., CHOC Children’s pediatrian-in-chief, MI2 is also studying how new technology is impacting the delivery of pediatric medicine.


“A sizable void exists in pediatric medicine in the areas of regenerative medicine, genomic medicine, robotic surgery, artificial intelligence, nanotechnology, biomedical informatics and decision support/outcomes analysis,” Dr. Chang said. “MI2 is an informal venue providing the hospital with a myriad of ideas regarding research and development in these key emerging areas, as well as other emerging technologies.”

MI2 Summer 2013 Internships Available

Three interns were selected for the inaugural MI2 2012 Summer Internship, where they had the opportunity to assist with projects, gain clinical exposure, and present research and topics at the monthly meetings. The first program of its kind in the nation, the MI2 Summer Internship Program is available for high school, undergraduate and graduate students.


Anthony Chang, MD MBA MPH


Pediatrics 2040: Future Trends and Emerging Innovations in the Next 25 Years

October 3 – 5, 2013

Disneyland Grand Californian Hotel® & Spa, Anahiem

The next 25 years are certain to completely transform medicine. “Pediatrics 2040” is the first meeting of its kind in the nation for physicians, healthcare administrators and other healthcare providers interested the impact of emerging technology and trends on the future delivery of pediatric healthcare.

In addition to the emerging areas – Regenerative Medicine, Genomic Medicine, Robotic Surgery, Artificial Intelligence and Nanotechnology, this comprehensive three-day conference covers:

  • Healthcare policy and finance
  • Innovative research
  • Global health
  • Pediatric epidemiology
  • Healthcare delivery models
  • Social media tools
  • Computer technology

“Pediatrics 2040” is a partnership of CHOC Children’s, the University of California, Irvine, School of Medicine; and the American Academy of Pediatrics.

Curious to learn more? For more information about MI2 monthly meetings, “Pediatrics 2040” or how to support or recommend candidates for the 2013 internship program, please contact Anthony Chang, M.D., at



CHOC 2020 Strategic Planning Process is Underway

CHOC Children’s has launched our strategic planning process, “CHOC 2020.” As the name suggests, the product of this visioning effort will be a comprehensive road map to guide our organization through the next seven years — an era that will bring dramatic change for CHOC as well as our surrounding environment.

The Process
CHOC 2020 is being overseen by a steering committee comprised of leadership from CHOC and CHOC Children’s at Mission Hospital, our Board of Directors and medical staff. We also have engaged Navigant Consulting, Inc., one of the nation’s leading healthcare planning firms, to assist us. Initial efforts included a comprehensive review of market and internal data, along with significant input and insights from key stakeholders and constituency groups, including physicians, through interviews, focus group, and meetings.

At the MEC retreat in October, the agenda included a strategic planning session in which market forces were presented and physicians indicated their desired role in the strategic planning process.    This was followed by a strategic planning retreat in November, which was attended by more than 40 organizational stakeholders, more than half of them physicians.  On December 8th, 41 physicians participated in another retreat which included dialog among CHOC physicians and hospital leaders around our mission, vision and values, as well as an exploration of strategic imperatives.

Emerging Themes
One clear theme that emerged out of the December 8th discussion was the interdependency among CHOC, community pediatricians and subspecialists practicing at the hospital, and the importance of continuing to advance alignment, communication and partnership among these vital stakeholders to ensure clinical access and excellence for the children we serve. These ideas relate to “clinical integration,” a concept we will continue to examine as we move forward with the strategic planning process.

Another idea clearly expressed as a priority was the importance of promoting innovation at CHOC to set new standards of distinction in pediatric care and position the hospital as an indispensible provider in the marketplace. Many modes of innovation were explored during this discussion, including research, education, clinical advancement and new program development. We will be tasked with prioritizing these and other areas of focus in the coming months, and I am eager to gain an understanding of your perspectives regarding CHOC’s top strategic initiatives.

Next Steps
Work groups assigned to each strategic priority will begin to meet in January.  The groups, each led by a physician and hospital representative, will define goals and begin to develop tactics, including resources, to meet those goals.  This will be followed by a prioritization process.

As always, we value your ideas and feedback and encourage you to share them by emailing

Managing and Improving Your Online Reputation

In this era of social media and online communications, negative comments can spread much faster and can reach a much wider audience than was ever possible by word of mouth.  Satisfied customers will share their positive experience with 3-5 people, but an unsatisfied customer will potentially complain about a negative experience to 10-20 others.  Social media platforms and physician graded websites multiply these numbers exponentially.

The good news is that there are ways to control the discussion, respond to and manage online reviews and comments – improving your reputation online. Following the links below, you will find some excellent resources gathered from the Internet to help with improving and managing your online reputation.*

Physician Reputation Management and Improvement Resources

Why Physicians Should Care About Online Reputation Management

Physician Online Reputation Management – 2 Realities

How Doctor-Grading Websites Can Impact Your Practice

Five Ways to Manage Your Online Reputation

Social Media Helps Doctors Manage their Online Reputation

Seven Ways Doctors Can Improve Their Online Reputation

A Doctor’s Reputation is not a Hospital’s Responsibility

One Physician’s Journey on Social Media (Video)

Another excellent way to enhance your online reputation and improve search engine results is by contributing content to CHOC’s social media channels.  If interested in learning more, please contact CHOC’s Public Relations Department at

*These resources are provided for educational purposes and reference only.  CHOC Children’s does not endorse any particular reputation management company or doctor-graded website.